May 21, 2024



OXFORD, England


,


April 29, 2024


/PRNewswire/ —

Caristo Diagnostics

,

a leading cardiac disease diagnostics company, has been named by

Newsweek

as one of

World’s Best Digital Health Companies

in diagnostics.

Caristo Diagnostics Logo


Newsweek

‘s inaugural ranking of the World’s Best Digital Health Companies includes 400 companies in seven segments including diagnostics, health records, medical management and telehealth. The ranking is based on in-depth analysis of thousands of companies’ financial performance and traffic data for websites and apps. In addition, market intelligence company Holon IQ provided data on the impact of companies’ innovations and the expertise of their leadership.

“Caristo is honored to be recognized by

Newsweek

as one of the World’s Best Digital Health Companies. This recognition validates the importance of Caristo’s CaRi-Heart

®

innovation as it for the first time gives healthcare professionals the ability to measure inflammation in the heart,” said


Frank Cheng

, CEO of Caristo

. “This recognition also speaks to the dedication and ingenuity of our team as well as our scientific, clinical and pharmaceutical industry partners around the world, who continuously push the boundaries to seek more effective ways to prevent, diagnose and treat coronary artery diseases.”

Caristo’s patented

CaRi-Heart

technology marks a novel scientific breakthrough that is radically transforming the traditional approach to heart disease prediction, prevention and management. The technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation, the otherwise invisible disease responsible for many fatal heart attacks and strokes. The

CaRi-Heart

technology has been shown to predict fatal and non-fatal cardiac events independently from routine clinical risk scores and standard CCTA interpretation, and can significantly impact treatment for coronary artery disease by transforming risk stratification and management of patients. Since 2018, exceptional validation results showing the

CaRi-Heart

technology’s ability to aid the prediction of heart attacks have been published in leading medical journals including the

Lancet

,

JACC

,

European Heart Journal

, and

Cardiovascular Research


.

The

CaRi-Heart

® technology is in clinical use in the UK, European Union and

Australia

.



About Caristo Diagnostics


Caristo Diagnostics



is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the

University of Oxford

, the world’s #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by

Nature



as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its

website



,

LinkedIn



and



X



.


Caristo Diagnostics contact:


Frank Cheng

,

CEO

[email protected]

Logo:

Cision
View original content:

SOURCE Caristo Diagnostics


link

Leave a Reply

Your email address will not be published. Required fields are marked *